Full-Time

Quality Assurance Leader

GE Healthcare

GE Healthcare

1-10 employees

Imaging, monitoring, and healthcare IT solutions

No salary listed

Munich, Germany

Hybrid

Bachelor's

Category
Biology & Biotech (1)
Required Skills
Supply Chain Management
Quality Assurance (QA)
Risk Management

Get referred to GE Healthcare

See people who can refer or advise you

Requirements
  • A degree in Pharmacy, Chemistry, Biology, Life Sciences, or another relevant scientific discipline.
  • Several years of relevant professional experience in pharmaceutical quality.
  • Expertise in Good Manufacturing Practice and Good Distribution Practice compliance, quality governance and quality systems, regulatory inspections and audits, Marketing Authorisation Holder and Pharmaceutical Entrepreneur operations, quality risk management, and supplier and outsourced activity oversight.
  • Proven leadership experience within a regulated pharmaceutical environment.
  • Strong knowledge of European Union Good Manufacturing Practice requirements, European Union Good Distribution Practice Guidelines, the German Arzneimittelgesetz and associated regulations, Marketing Authorisation Holder and Pharmaceutical Entrepreneur obligations, inspection and audit management, product complaint, defect, and recall management, and quality risk management principles and methodologies.
  • Fluency in German and English.
Responsibilities
  • Define and implement the quality strategy for the German Pharmaceutical Entrepreneur business, aligned with regional and global quality objectives.
  • Act as the senior quality representative for the German Pharmaceutical Entrepreneur and Marketing Authorisation Holder organisation.
  • Establish and maintain governance processes for identifying, assessing, escalating, and mitigating quality and compliance risks.
  • Drive quality, integrity, accountability, continuous improvement, and risk-based decision-making across the organisation.
  • Advise senior management on emerging quality, regulatory, and compliance risks and opportunities.
  • Ensure quality governance arrangements support compliance with applicable Marketing Authorisation Holder, Pharmaceutical Entrepreneur, Good Manufacturing Practice, Good Distribution Practice, and regulatory requirements.
  • Monitor quality-system effectiveness through quality metrics, trend analysis, management review, and risk-based oversight.
  • Ensure appropriate governance and escalation of significant quality events, compliance issues, and quality risks.
  • Assess emerging regulatory requirements and oversee implementation of actions needed to maintain compliance.
  • Provide quality leadership for quality-related Pharmaceutical Entrepreneur and Marketing Authorisation Holder obligations in Germany.
  • Collaborate with Regulatory Affairs, the Information Officer under §74a AMG, Qualified Persons, and external partners to maintain product compliance throughout the lifecycle.
  • Ensure quality oversight of product launches, variations, transfers, discontinuations, market actions, and recall activities.
  • Support management of product quality issues, market complaints, defect investigations, and product recalls.
  • Lead inspection readiness and represent the organisation during regulatory authority inspections, corporate audits, partner audits, and external assessments.
  • Provide strategic leadership in managing inspection and audit observations.
  • Ensure corrective and preventive actions are effective, sustainable, and monitored through governance processes.
  • Serve as a quality authority during significant regulatory interactions and escalations.
  • Ensure quality risks are identified, assessed, controlled, communicated, and reviewed using established risk-management methodologies.
  • Provide independent quality assessments and recommendations for significant business initiatives, product-related decisions, and compliance matters.
  • Escalate critical risks and emerging compliance concerns to governance bodies and senior leadership.
  • Ensure quality oversight of contract manufacturers and other GxP service providers.
  • Ensure supplier qualification, monitoring, and performance-management processes support regulatory compliance and product quality.
  • Build partnerships across Quality, Regulatory Affairs, Pharmacovigilance, Medical Affairs, Supply Chain, Commercial Operations, and Manufacturing.
  • Lead quality initiatives that strengthen compliance capability, operational effectiveness, and organisational performance.
Desired Qualifications
  • An advanced degree.
  • Previous experience as a Qualified Person or Responsible Person with Marketing Authorisation Holder experience.

GE Healthcare Systems provides medical technologies and digital infrastructure to improve diagnosis, treatment, and monitoring of patients. Its products include imaging systems, mobile diagnostic devices, patient monitoring tools, and healthcare IT software that work together as hardware, software, and services to support hospitals, clinics, and researchers. The company differentiates itself with a large, integrated ecosystem, strong focus on AI analytics, and a global service network backed by substantial R&D investment. Its goal is to improve patient outcomes and the efficiency of healthcare delivery by enabling accurate diagnoses, effective treatments, and scaled operations.

Company Size

1-10

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

1892

Get referred to GE Healthcare

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Photonova Spectra won CE Mark on August 31, 2026, opening Europe sales.
  • Q2 2026 orders rose 11.1%, with 1.15x book-to-bill and record backlog.
  • Vivid cardiovascular ultrasound and ABUS breast screening launches broaden 2026 revenue opportunities.

What critics are saying

  • Patient Care Solutions revenue fell 13.5% in Q2 2026; management is reviewing a sale.
  • Jay Saccaro left in August 2026; William Grogan starts September 14, 2026.
  • If PCS recovery slips into 2027, GE HealthCare becomes a slower-growth imaging vendor.

What makes GE Healthcare unique

  • Photonova Spectra’s Deep Silicon CT differentiates GE HealthCare with photon-counting imaging.
  • GE HealthCare spans imaging, pharma diagnostics, ultrasound, and monitoring across hospital workflows.
  • The July 2026 backlog of $23.9 billion reflects sticky installed-base demand and services.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Tuition Reimbursement

Relocation Assistance

Company News

Yahoo Finance
Sep 1st, 2026
GE HealthCare secures CE mark for Photonova Spectra photon-counting CT system

GE HealthCare has received CE mark approval for its Photonova Spectra photon-counting computed tomography system, enabling commercial sales in markets recognising CE marking. The clearance follows US Food and Drug Administration approval and Japanese regulatory clearance in March 2026. The system uses GE HealthCare's Deep Silicon detector technology to deliver ultra-high definition spectral and spatial imaging. It processes data volumes up to 50 times greater than conventional CT systems, utilising Nvidia's accelerated computing platform. Clinical collaborations are underway at UZ Brussel in Belgium and Rigshospitalet in Denmark to evaluate the system across cardiology, neurology, oncology and musculoskeletal imaging. The CE mark follows more than $5 billion in innovation investment by GE HealthCare.

Yahoo Finance
Aug 31st, 2026
Vertex Pharmaceuticals shows promise while GE HealthCare and Wells Fargo face challenges

Vertex Pharmaceuticals has emerged as a standout S&P 500 stock, according to StockStory's analysis. The company, which focuses on developing transformative medicines for serious diseases including cystic fibrosis and sickle cell disease, boasts a market capitalisation of $137.3 billion. Meanwhile, StockStory recommends avoiding two large-cap stocks. GE HealthCare, spun off from General Electric in 2023, faces concerns over stagnant organic revenue growth and declining operating margins. The medical equipment provider has a market cap of $32.4 billion. Wells Fargo also made the avoid list. The diversified financial services company, with a $262.2 billion market cap, has seen its net interest margin shrink by 33.6 basis points over two years, suggesting increased competition or declining loan profitability.

Associated Press
Aug 28th, 2026
GE HealthCare launches three new Vivid cardiovascular ultrasound systems for diverse care settings

GE HealthCare has introduced three new cardiovascular ultrasound systems to its Vivid portfolio: Vivid Explorer 1, Vivid Advanced 1, and Vivid Focus 1. The systems were unveiled at the European Society of Cardiology Congress 2026 in Munich, Germany. Each system targets different clinical settings whilst sharing a common technology foundation with the ultra-premium Vivid Pioneer. Vivid Explorer is designed for high-volume echo labs, Vivid Advanced for mid-size hospitals and cardiology practices, and Vivid Focus for everyday cardiac imaging. All three systems use cSound imaging technology and include AI-enabled automation tools to streamline echo workflows. The systems have received CE Mark approval but are awaiting US FDA 510(k) clearance and are not yet available for sale in the United States.

Yahoo Finance
Aug 3rd, 2026
GE HealthCare launches Invenia ABUS Prime and StreamVue for breast cancer screening

GE HealthCare has launched Invenia ABUS Prime and ABUS StreamVue, expanding its breast imaging portfolio with solutions for supplemental screening in women with dense breasts. The Invenia ABUS Prime system has been installed at BeSound in Los Angeles, marking one of the first US installations. ABUS StreamVue is a browser-based reading solution enabling remote exam review across imaging networks. The system received FDA 510(k) clearance and CE Marking. Studies show 40% of women have dense breasts, carrying four to six times higher breast cancer risk. Research indicates mammography may miss one-third of cancers in dense breasts. Invenia ABUS Prime features AI-enabled tools including Scan Quality Assessment and can increase scan speed by up to 40%. The AI Assistant has demonstrated a 33% reduction in reading time.

Yahoo Finance
Jul 29th, 2026
GE HealthCare Q2: Orders up 11%, backlog hits record $23.9B amid Patient Care struggles

GE HealthCare Technologies reported second-quarter results with orders rising 11% year-over-year and backlog reaching a record $23.9 billion. Revenue grew 3.5% organically to $5.3 billion, driven by Advanced Imaging Solutions and Pharmaceutical Diagnostics, which posted organic growth of 5% and 14.6% respectively. Patient Care Solutions remained weak, with revenue falling 13.5% due to component shortages and fulfilment problems. Management is reviewing strategic options for the segment, including a potential sale. The company maintained its full-year outlook of 3–4% organic sales growth, adjusted earnings per share of $4.80–$5.00, and approximately $1.6 billion in free cash flow. CFO Jay Saccaro is departing, with George Newcomb serving as interim CFO.